NasdaqGS:ENTABiotechs
Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives
Enanta Pharmaceuticals (ENTA) has just posted Q2 2026 results with revenue of US$17.2 million and a basic EPS loss of US$0.45, while trailing twelve month figures show revenue of US$69.2 million and a basic EPS loss of US$2.47. Over recent quarters the company has seen revenue move between US$14.9 million and US$18.6 million, with quarterly basic EPS losses ranging from roughly US$0.41 to US$1.06 and trailing twelve month net losses of US$62.0 million. For investors, the story this quarter is...